主要学习经历
2001-2005, 厦门大学, 生物科学, 理学学士
2005-2012, 厦门大学, 生物化学与分子生物学, 理学博士
科研工作经历
2009-至今, 厦门大学NIDVD, 病毒性肝炎研究组, 组长
2012-2015, bet体育365官网正规, 助理教授
2016-2019, bet体育365官网正规, 副教授
2019-至今, bet体育365官网正规, 教授
主要研究方向
本研究小组重点发展乙型病毒性肝炎创新诊疗技术和药物，围绕这一目标开展分子病毒学、免疫学、临床检验诊断学、流行病学和转化医学研究，具体主要包括：
（1）针对持续性病毒感染的治疗性抗体与治疗性疫苗研究；
（2）慢性乙型肝炎治疗应答和转归指导预测诊断新靶标研究；
（3）模拟人类HBV感染致病的细胞与动物模型研究；
（4）HBV感染及其相关疾病的血清与分子流行病学研究；
（5）持续性病毒感染与肿瘤的免疫逃逸机制及治疗新技术。
近年来累计发表SCI研究论文60余篇；已有4项发明专利获得国内外14件授权，研究成果转化的诊断产品累计9项获得NMPA注册证书，1项欧盟CE认证，多次获得福建省及厦门市科技进步奖等荣誉。
代表性论文
1. Zhang TY†, Chen HY†, Cao JL†, Xiong HL, Li TL, Kang XZ, Zhao JH, Yin B, Yuan Q*, Xue D*, Xia NS*. Yuan YA. Structural and functional analyses of the Hepatitis B virus X protein BH3-like domain and its interaction with Bcl-xL. Nature Communications. 2019;10(1):3192.
2. Zhang TY†, Guo XR†, Wu YT†, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Chen PJ, Zhang J*, Yuan Q* and Xia NS*. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2019. DOI:10.1136/gutjnl -2018-317725
3.Yuan L†, Zhang Y†, Liu X†, Chen Y, Zhang L, Cao J, Li X, Wang M, Wu K, Zhang J, Liu G, Tang Q, Yuan Q*, Cheng T*, Xia N*. Agonist c-Met Monoclonal Antibody Augments the Proliferation of hiPSC-derived Hepatocyte-Like Cells and Improves Cell Transplantation Therapy for Liver Failure in Mice. Theranostics. 2019; 9(7):2115-2128.
4. Zhang YL†, Gao Y†, Cao JL, Zhao JH, Zhang TY, Yang CL, Xiong HL, Wang YB, Ou SH*, Cheng T, Chen CR*, Yuan Q*, Xia NS. Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus. Emerg Microbes Infect. 2019;8(1):724-733.
5. Liu X†, Yuan L†, Zhang L, Mu Y, Li X, Liu C, Lv P, Zhang Y, Cheng T, Yuan Q*, Xia N, Chen X, Liu G*. Bioinspired Artificial Nanodecoys for Hepatitis B Virus. Angewandte chemie-international edition. 2018; 57(38):12499-12503.
6. Zhang JF†, Xiong HL†, Cao JL, Wang SJ, Guo XR, Lin BY, Zhang Y, Zhao JH, Wang YB, Zhang TY*, Yuan Q*, Zhang J, Xia NS. A cell-penetrating whole molecule antibody targeting intracellular HBx suppress hepatitis B virus via TRIM21-dependent pathway, Theranostics.2018, 8(2): 549-562.
7. Yuan L†, Liu X†, Zhang L, Zhang Y, Chen Y, Li X, Wu K, Cao J, Hou W, Que Y, Zhang J, Zhu H, Yuan Q, Tang Q, Cheng T, Xia N. Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection. Emerg Microbes Infect. 2018;7(1):144.
8. Zhang TY†, Yuan Q†,*, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, Sun CP, Wu CR, Zhang JF, Zhang Y, Cao JL, Guo XR, Liu X, Mo XB, Luo WX, Cheng T, Chen YX, Tao MH, Shih JW, Zhao QJ, Zhang J, Chen PJ, Yuan YA*, Xia NS*, Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut, 2016, 65(4): 658-71.
9. Fan F†, He Z†, Kong LL†, Chen Q†, Yuan Q†, Zhang S, Ye J, Liu H, Sun X, Geng J, Yuan L, Hong L, Xiao C, Zhang W, Sun X, Li Y, Wang P, Huang L, Wu X, Ji Z, Wu Q, Xia NS, Gray NS, Chen L, Yun CH*, Deng X*, Zhou D*. Pharmacological targeting of kinases mst1 and mst2 augments tissue repair and regeneration. Science Translational Medicine, 2016; 8(352), 352ra108.
10. Fan R†, Sun J†, Yuan Q†, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N*, Hou J*. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016, 65(2):313-20.
11. Song LW†, Wang YB†, Fang LL, Wu Y, Yang L, Chen JY, Ge SX, Zhang J, Xiong YZ, Deng XM, Min XP*, Zhang J, Chen PJ, Yuan Q*, Xia NS. Rapid fluorescent lateral-flow immunoassay for hepatitis B virus genotyping. Anal Chem. 2015;87(10):5173-80.
12. Song LW†, Liu PG†, Liu CJ, Zhang TY, Cheng XD, Wu HL, Yang HC, Hao XK, Yuan Q*, Zhang J, Kao JH, Chen DS, Chen PJ*, Xia NS*. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin Microbiol Infect. 2015; 21(2):197-203.
13. Yuan Q, Song LW, Liu CJ, Li Z, Liu PG, Huang CH, Yan Y, Ge SX, Wang YB, Peng CY, Zhang J*, Kao JH, Chen DS, Chen PJ*, Xia NS*. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut. 2013; 62(1):182-4. (IF: 17.943)
14. Huang CH†, Yuan Q†, Chen PJ, Zhang YL, Chen CR, Zheng QB, Yeh SH, Yu H, Xue Y, Chen YX, Liu PG, Ge SX, Zhang J*, Xia NS*. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol. 2012; 57(4):720-9.
